Senti Biosciences Announces FDA Orphan Drug Designation for SENTI-202 in Relapsed/Refractory Hematologic Malignancies Including AML

　　【Pharmaceutical Network Product InformationRecently, Senti Biosciences, a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its product SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). This news brings new hope to patients who struggle to benefit from traditional treatments.
 

Senti Biosciences is committed to developing the next generation of cell and gene therapies by leveraging its proprietary Gene Circuit platform. Founded with the goal of creating a new generation of smarter drugs to tackle complex diseases through innovative approaches, the company has assembled a team of seasoned professionals with deep technical expertise in cell and gene therapy development.
 

SENTI-202, as Senti Biosciences' off-the-shelf logic-gated CD33 or FLT3 non-EMCN CAR-NK cell therapy candidate, features a unique design concept. Acute myeloid leukemia (AML) is a highly challenging hematologic malignancy, with approximately 20,800 new cases diagnosed annually in the United States. Moreover, 60% of patients experience recurrence or succumb to the disease within 12 months, and the average survival duration is merely 5.3 months, indicating a significant unmet clinical need. AML cells exhibit high heterogeneity, making it difficult for traditional therapies to precisely target and eliminate all cancer cells while also sparing healthy cells from damage. SENTI-202 aims to overcome these challenges by selectively targeting and eradicating hematologic malignant cells expressing CD33 and/or FLT3, such as those in AML and myelodysplastic syndromes (MDS), while preserving healthy bone marrow cells.
 

Currently, SENTI-202 is undergoing Phase 1 clinical trial (NCT06325748) evaluation. The results from the published clinical trial data are encouraging. At the recommended Phase 2 dose, 67% (2/3) of patients achieved a composite complete response (cCR). Among all evaluable patients across all dose levels, 71% (5/7) demonstrated an objective response, with 57% (4/7) achieving cCR. Notably, all four patients who achieved cCR reached MRD-negative status (measurable residual disease-negative), with the longest duration of response exceeding 8 months and still ongoing. In terms of safety, the therapy performed well, with no dose-limiting toxicity reported and the maximum tolerated dose not yet reached. Based on these results, the preliminary recommended Phase 2 dose is set at 1.5x10⁹ CAR-NK cells, administered on days 0, 7, and 14 in a 28-day cycle following lymphodepleting chemotherapy.
 

FDA's Orphan Drug Designation aims to promote the development of drugs for rare diseases or conditions (diseases affecting fewer than 200,000 people in the United States). With this designation, Senti Biosciences is eligible for a series of incentives, such as tax credits, certain FDA fee exemptions for clinical trials, and the potential for seven years of market exclusivity upon drug approval. This not only provides strong support for the subsequent development of SENTI-202 but also further validates the company's innovative approach of using gene circuits to overcome AML heterogeneity and protect healthy cells.
 

A representative of Senti Biosciences stated that SENTI-202, as a potential treatment option for relapsed/refractory AML, continues to show promising prospects. There is a significant unmet need for the treatment of relapsed/refractory AML, and the orphan drug designation received by SENTI-202 further confirms the value of its novel approach while highlighting the urgency of developing new and effective treatment options.
 

Looking ahead, as the SENTI-202 clinical trial progresses, it is hoped that this innovative therapy will bring tangible clinical benefits to patients with relapsed/refractory hematologic malignancies, transforming the treatment challenges and prognosis for these patients. Meanwhile, Senti Biosciences' exploration and breakthroughs in gene circuit technology are also expected to bring new development ideas to the field of cell and gene therapies, driving the emergence of more innovative treatments.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.